Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record details. This replaces the trial information with an access-denied screen.SummaryDifference22%

- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedRevision metadata on the page was updated from v3.6.5 to v3.6.6, indicating a minor version update to the page’s backend or documentation. This change does not modify the study content or data presented on the page.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page revision label was updated to v3.6.5, indicating a new site build rather than changes to the study details.SummaryDifference0.0%

- Check62 days agoChange DetectedIPD (Individual Participant Data) data-sharing plan added and related terminology updated. Study Protocol and Statistical Analysis Plan are now linked, and MeSH terms and record history metadata expanded to improve indexing and transparency of the trial record.SummaryDifference78%

- Check69 days agoChange DetectedA new revision tag (Revision: v3.6.4) is shown, and several non-core study documents/listings were removed from the study record, reflecting a documentation cleanup on the page.SummaryDifference21%

- Check90 days agoChange DetectedThe page revision has been updated from v3.6.2 to v3.6.3, reflecting a newer version of the page content. The change does not modify displayed study information.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.